

ELECTRONIC INFORMATION DISCLOSURE STATEMENT

Electronic Version v18

Stylesheet Version v18.0

Title of Invention	24 HYDROXYVITAMIN D, ANALOGS AND USES THEREOF																																																																																
<p>Application Number: 09/753697 *09/753697*</p> <p>Confirmation Number: 1609</p> <p>First Named Applicant: Charles Bishop</p> <p>Attorney Docket Number: 0176209316</p> <p>Art Unit: 1617</p> <p>Examiner: Theodore J. Criares</p> <p>Search string: (2383446 or 3697559 or 3741996 or 4160803 or 4362710 or 4508651 or 4588716 or 4661294 or 4698328 or 4717721 or 4902481 or 5141719 or 5157135 or 5205989 or 5219528 or 5232836 or 5264184 or 5264618 or 5334740 or 5338532 or 5372996 or 5417923 or 5488120 or 5527524 or 5554386 or 5597575 or 5614513 or 5637742 or 5661025 or 5739271 or 5795882 or 6537982).pn.</p> <p>US Patent Documents</p> <p>Note: Applicant is not required to submit a paper copy of cited US Patent Documents</p> <table border="1" style="width: 100%; border-collapse: collapse; text-align: center;"> <thead> <tr> <th>init</th> <th>Cite.No.</th> <th>Patent No.</th> <th>Date</th> <th>Patentee</th> <th>Kind</th> <th>Class</th> <th>Subclass</th> </tr> </thead> <tbody> <tr> <td><input checked="" type="checkbox"/></td> <td>1</td> <td>2383446</td> <td>1941-06-04</td> <td>Calcott et al</td> <td></td> <td></td> <td></td> </tr> <tr> <td><input type="checkbox"/></td> <td>2</td> <td>3697559</td> <td>1972-10-10</td> <td>DeLuca et al.</td> <td></td> <td></td> <td></td> </tr> <tr> <td><input type="checkbox"/></td> <td>3</td> <td>3741996</td> <td>1973-06-26</td> <td>DeLuca et al.</td> <td></td> <td></td> <td></td> </tr> <tr> <td><input type="checkbox"/></td> <td>4</td> <td>4160803</td> <td>1979-07-10</td> <td>Potts</td> <td></td> <td></td> <td></td> </tr> <tr> <td><input type="checkbox"/></td> <td>5</td> <td>4362710</td> <td>1982-12-07</td> <td>Watanabe</td> <td></td> <td></td> <td></td> </tr> <tr> <td><input type="checkbox"/></td> <td>6</td> <td>4508651</td> <td>1985-04-02</td> <td>Baggiolini et al</td> <td></td> <td></td> <td></td> </tr> <tr> <td><input type="checkbox"/></td> <td>7</td> <td>4588716</td> <td>1986-05-13</td> <td>DeLuca et al</td> <td></td> <td></td> <td></td> </tr> <tr> <td><input type="checkbox"/></td> <td>8</td> <td>4661294</td> <td>1987-04-28</td> <td>Holick et al</td> <td></td> <td></td> <td></td> </tr> <tr> <td><input checked="" type="checkbox"/></td> <td>9</td> <td>4698328</td> <td>1987-10-06</td> <td>Neer et al</td> <td></td> <td></td> <td></td> </tr> </tbody> </table>		init	Cite.No.	Patent No.	Date	Patentee	Kind	Class	Subclass	<input checked="" type="checkbox"/>	1	2383446	1941-06-04	Calcott et al				<input type="checkbox"/>	2	3697559	1972-10-10	DeLuca et al.				<input type="checkbox"/>	3	3741996	1973-06-26	DeLuca et al.				<input type="checkbox"/>	4	4160803	1979-07-10	Potts				<input type="checkbox"/>	5	4362710	1982-12-07	Watanabe				<input type="checkbox"/>	6	4508651	1985-04-02	Baggiolini et al				<input type="checkbox"/>	7	4588716	1986-05-13	DeLuca et al				<input type="checkbox"/>	8	4661294	1987-04-28	Holick et al				<input checked="" type="checkbox"/>	9	4698328	1987-10-06	Neer et al			
init	Cite.No.	Patent No.	Date	Patentee	Kind	Class	Subclass																																																																										
<input checked="" type="checkbox"/>	1	2383446	1941-06-04	Calcott et al																																																																													
<input type="checkbox"/>	2	3697559	1972-10-10	DeLuca et al.																																																																													
<input type="checkbox"/>	3	3741996	1973-06-26	DeLuca et al.																																																																													
<input type="checkbox"/>	4	4160803	1979-07-10	Potts																																																																													
<input type="checkbox"/>	5	4362710	1982-12-07	Watanabe																																																																													
<input type="checkbox"/>	6	4508651	1985-04-02	Baggiolini et al																																																																													
<input type="checkbox"/>	7	4588716	1986-05-13	DeLuca et al																																																																													
<input type="checkbox"/>	8	4661294	1987-04-28	Holick et al																																																																													
<input checked="" type="checkbox"/>	9	4698328	1987-10-06	Neer et al																																																																													

TJ Criares 6/15/04

<input checked="" type="checkbox"/>	10	4717721	1988-01-25	DeLuca et al
<input checked="" type="checkbox"/>	11	4902481	1990-02-20	Clark et al
<input checked="" type="checkbox"/>	12	5141719	1992-08-25	Fernwood et al
<input checked="" type="checkbox"/>	13	5157135	1992-10-20	Tsuji et al
<input checked="" type="checkbox"/>	14	5205989	1993-04-27	Aysta
<input checked="" type="checkbox"/>	15	5219528	1993-06-15	Clark
<input checked="" type="checkbox"/>	16	5232836	1993-08-03	Bouillon et al
<input checked="" type="checkbox"/>	17	5264184	1993-11-23	Aysta et al
<input checked="" type="checkbox"/>	18	5264618	1993-11-23	Felgner et al
<input checked="" type="checkbox"/>	19	5334740	1994-08-02	Takahashi et al
<input checked="" type="checkbox"/>	20	5338532	1994-08-16	Tomalia et al
<input checked="" type="checkbox"/>	21	5372996	1994-12-13	Labrie
<input checked="" type="checkbox"/>	22	5417923	1995-05-23	Bojanic et al
<input checked="" type="checkbox"/>	23	5488120	1996-01-30	Knutson et al
<input checked="" type="checkbox"/>	24	5527524	1996-06-18	Tomalia et al
<input checked="" type="checkbox"/>	25	5554386	1996-09-10	Groman et al
<input checked="" type="checkbox"/>	26	5597575	1997-01-28	Breitbarth
<input checked="" type="checkbox"/>	27	5614513	1997-03-25	Knutson et al
<input checked="" type="checkbox"/>	28	5637742	1997-06-10	Valles et al
<input checked="" type="checkbox"/>	29	5661025	1997-08-26	Szoka, Jr. et al
<input checked="" type="checkbox"/>	30	5739271	1998-04-14	Sridhar et al
<input checked="" type="checkbox"/>	31	5795882	1998-08-18	Bishop et al
<input checked="" type="checkbox"/>	32	6537982	2003-03-25	Bishop et al


Remarks


Note: Remarks are not for responding to an office action.

This is the first of one (1) electronic submissions and one paper filing submission of foreign patent documents and non-patent literature. All are considered to be part of the same, single IDS. Citation of these references is respectfully requested. No concession is made that these documents are prior art, and Applicant expressly reserves the right to antedate the documents as may be appropriate. The \$180 fee is included with the paper filing submission.

TJ Chung 6/15/04

Signature

Examiner Name	Date
	6/15/04



PTO/SB/08A

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	09/753,697
				Filing Date	January 3, 2001
				First Name Inventor	Charles W. Bishop
				Group Art Unit	1617
Examiner Name	Theodore J. Criares				
Attorney Docket Number	017620-9316				
Sheet	1	of	1		

U.S. PATENT DOCUMENTS				
Examiner Initials		U.S. Patent Document Number	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document

--	--	--	--	--

FOREIGN PATENT DOCUMENTS						
Examiner Initials	Country Code	Foreign Patent Document Number	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document	Translation	English Abstract
TK	Belgium	877 356	Wisconsin Alumni Research Foundation	10/15/79		
	Japan	5320127	Nisshin Flour Milling Co.	09/29/93		
	Japan	6025039	Kurary Co. Ltd.	02/01/94		
	Japan	62000033	General Hospital	10/15/86		
	EP	0197514	General Hospital	10/15/86		
	EP	0390097	Nisshin Flour Milling Co.	10/03/90		
	PCT	WO 84/04527	Wisconsin Alumni Research Foundation	11/22/84		
	PCT	WO 87/00834	Leo Pharmaceutical Products, Ltd.	02/12/87		
	PCT	WO 90/10620	Wisconsin Alumni Research Foundation	09/20/90		
	PCT	WO 92/21355	Procter & Gamble	12/10/92		
✓	PCT	WO 93/07883	ISIS Pharmaceuticals	04/29/93		
	PCT	WO 96/40153	Bone Care International	12/19/96		

Examiner Signature		Date Considered	6/15/04
--------------------	--	-----------------	---------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer. Patent and Trademark Office, Washington, DC 0231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB number.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

Use as many sheets as necessary)

Sheet

1

of

5

Complete if Known

Application Number	09/753,697
Filing Date	January 3, 2001
First Named Inventor	Charles W. Bishop
Group Art Unit	1617
Examiner Name	Theodore J. Criares
Attorney Docket Number	017620-9316

MAR 15 2004

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, pages(s), volume-issue numbers(s), publisher, city and/or country where published.

<i>AK</i>	AA	Barton, D. et al., "Synthetic Uses of Steroidal Ring & Diene Protection: 22,23-Dihydroergosterol," <i>JCS Perkin I</i> , (1976) pp. 821-826.
<i>AK</i>	AB	Beer, T. et al., "Weekly High-Dose Calcitriol and Docetaxel in Metastatic Androgen-Independent Prostate Cancer," <i>Journal of Clinical Oncology</i> , (Jan. 2003) 21:1:123-128.
	AC	Blazsek, I. et al., "Combined Differentiation Therapy in Myelodysplastic Syndrome with Retinoid Acid, 1 α ,25-Dihydroxyvitamin D ₃ , and Prednisone," 16:4:259-264 (Abstract) <i>Novel Data</i>
<i>AK</i>	AD	Brautbar, N. "Osteoporosis: Is 1,25-(OH) ₂ D ₃ of Value in Treatment?" <i>Nephron</i> (1986) 44:161-166.
	AE	Braunwald, E. et al., <i>Harrison's Principles of Internal Medicine</i> : Part Eleven, "Disorders of Bone and Mineral Metabolism," Chapter 335, McGraw-Hill, New York, (1987) pp. 1860-1865.
	AF	Brown, J.P. et al., "Serum Bone Gla-Protein: A Specific Marker for Bone Formation in Postmenopausal Osteoporosis," <i>Lancet</i> , (1984) 1:1091-1093.
	AG	Caniggia, A. et al., "Effect of a Long-Term Treatment with 1,25-Dihydroxyvitamin D ₃ on Osteocalcin in Postmenopausal Osteoporosis," <i>Calcified Tissue Int.</i> , (1986) 38:328-332.
	AH	Christiansen, C. et al., "Prevention of Early Postmenopausal Bone Loss: Controlled 2-Year Study in 315 Normal Females," <i>Europ J Clin Inves.</i> , (1980) 10:273-279.
	AI	Crump, D.R. et al., "(22S)-Hydroxyvitamin D ₄ ," <i>J.C.S. Perkins Trans. I</i> , (1973) pp. 2731-2733.
	AJ	Cho, Y.L. et al., "Combined Effects of 1,25-Dihydroxyvitamin D ₃ and Platinum Drugs on the Growth of MCF-7 Cells," <i>Cancer Research</i> , (June 1991) 51:2848-2853.
	AK	Defacque, H. et al., "Different Combinations of Retinoids and Vitamin D ₃ Analogs Efficiently Promote Growth Inhibition and Differentiation of Myelomonocytic Leukemia Cell Lines," <i>J. Pharmacology and Experimental Therapeutics</i> , (1994) 271:193-199.
	AL	DeLuca et al., "Synthesis, Biological Activity, and Metabolism of 22,23- ³ H-Vitamin D ₄ ," <i>Arch. Biochem. Biophys.</i> , (1968) 124:122-128.
	AM	Duda et al., "1,25-Dihydroxyvitamin D Stimulation Test for Osteoblast Function in Normal and Osteoporotic Postmenopausal Women," <i>J. Clin. Inves.</i> , (1987) 79:1249-1253.
	AN	Endo, K. et al., "Effect of Combination Treatment with Vitamin D Analog (OCT) and a Bisphosphonate (AHPBP) in a Nude Mouse Model of Cancer-Associated Hypercalcemia," <i>Journal of Bone and Mineral Research</i> , (1998) 13:9:1378-1383.
	AO	Foldes, J. et al., "Long Term Treatment with 1 α (OH)D ₃ for Postmenopausal Osteoporosis: Efficacy and Safety," <i>Osteoporosis</i> , (1987) 2:971-973.

Examiner Signature	<i>TJ Criares</i>	Date Considered	6/15/04
--------------------	-------------------	-----------------	---------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB number.

Substitute for form 1449B/PTO			Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Application Number	09/753,697
			Filing Date	January 3, 2001
			First Named Inventor	Charles W. Bishop
			Group Art Unit	1617
			Examiner Name	Theodore J. Criares
			Attorney Docket Number	017620-9316
Sheet	2	of	5	

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, pages(s), volume-issue numbers(s), publisher, city and/or country where published.

AP	Gallagher, J.C. et al., "Effects of Increasing Doses of 1 α -Hydroxyvitamin D ₂ on Calcium Homeostasis in Postmenopausal Osteopenic Women," <i>J. Bone Min. Res.</i> , (1994) 9:5:607-614.
AQ	Grab, W. <i>Z. Physiol. Chem.</i> , (1936) 243:63-89.
AR	Guidelines for the Clinical Evaluation of Drugs Used in the Treatment of Osteoporosis, HEW (FDA) 80-3094, (1979) pp. 5-6.
AS	Hershberger, P. et al. "Calcitriol (1,25-Dihydroxycholecalciferol) Enhances Paclitaxel Antitumor Activity <i>in Vitro</i> and <i>in Vivo</i> and Accelerates Paclitaxel-induced Apoptosis," <i>Clinical Cancer Research</i> , (April 2001) 7:1043-1051.
AT	Hoikka, V. et al., "Treatment of Osteoporosis with 1-Alpha-Hydroxycholecalciferol and Calcium," <i>Acta. Med. Scand.</i> (1980) 207:221-224.
AU	Holick, M.F., "Noncalcemic Actions of 1,25-Dihydroxyvitamin D ₃ and Clinical Applications", <i>Bone</i> , (1995) 17:2:107S-110S.
AV	Horst et al., "Quantitation of Vitamin D and its Metabolites and Their Plasma Concentrations in Five Species of Animals," <i>Anal. Biochem.</i> , (1981) 116:189-203.
AW	Horst et al., "Discrimination in the Metabolism of Orally Dosed Ergocalciferol and Cholecalciferol by the Pig, Rat and Chick," <i>Biochem. J.</i> , (1982) 204:185-189.
AX	Johnson, C. et al., "Vitamin D-related Therapies in Prostate Cancer," <i>Cancer and Metastasis Review</i> 21, (2002) pp. 147-158.
AY	Kanis, J.A. et al., "Guidelines for Clinical Trials in Osteoporosis, A Position Paper of the European Foundation for Osteoporosis," <i>Osteoporosis Int.</i> , (1991) 1:182-188.
AZ	Kim, S. et al., "Potentiation of 1,25-Dihydroxyvitamin D ₃ -Induced Differentiation of Human Promyelocytic Leukemia Cells into Monocytes by Costunolide, a Germacranolide Sesquiterpene Lactone," <i>Biochem. Pharmacology</i> , (2002) 64:1233-1242.
BA	Knutson, et al., "Metabolism of 1 α -Hydroxyvitamin D ₂ to activated Dihydroxyvitamin D ₂ Metabolites Decreases Endogenous 1 α ,25-Dihydroxyvitamin D ₃ in Rats and Monkeys," <i>Endocrinology</i> , (1995) 136:11:4749-4753.
BB	Kocienski, P.J. et al., "Calciferol and its Relatives. A Synthesis of Vitamin D ₄ ," <i>J.C.S. Perkins I</i> , (1979) pp. 1290-1293.
BC	Londowski, J.M. et al., "Biological Activity of the C-1, C-3, C-25, β -D-Glucopyranosides of 1,25-Dihydroxyvitamin D ₃ ," <i>J. Pharmacology Expr. Ther.</i> , (1986) 237:3:837-840.

Examiner Signature	<i>TJ Criares</i>	Date Considered	6/15/02
--------------------	-------------------	-----------------	---------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB number.

Substitute for form 1449B/PTO			Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Application Number	09/753,697	
			Filing Date	January 3, 2001	
			First Named Inventor	Charles W. Bishop	
			Group Art Unit	1617	
			Examiner Name	Theodore J. Criares	
Sheet	3	of	5	Attorney Docket Number	017620-9316

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, pages(s), volume-issue numbers(s), publisher, city and/or country where published.
----------------------	--

<i>th</i>	BD	Majewski, <i>et al.</i> , "Inhibition of Tumor Cell-Induced Angiogenesis by Retinoids, 1,25-Dihydroxyvitamin D ₃ and their Combination," <i>Cancer Letters</i> , (1993) 75:35-39.	
<i>th</i>	BE	Martin and DeLuca, "Calcium Transport," <i>Am. J. Physiol.</i>, 216:1352-1359.	<i>Need Date</i>
<i>th</i>	BF	Mathias, C.J. et al., "Tumor-Selective Radiopharmaceutical Targeting Via Receptor-Mediated Endocytosis of Gallium-67-Deferoxamine-Folate," <i>J. Nucl. Med.</i> (1996), 37(6):1003-1008.	
	BG	McDonald, F.G., "The Multiple Nature of Vitamin D," <i>J. Biol. Chem.</i> 114, (1936) 1xv.	
	BH	<i>Merck Index</i> , S. Budavari (ed.), 11th ed., Merck & Co., Rahway, N.J. (1989) pp. 1579, #9930	
	BI	Moffatt, K. et al., "1 α ,25-Dihydroxyvitamin D ₃ and Platinum Drugs Act Synergistically to Inhibit the Growth of Prostate Cancer Cell Lines," <i>Clinical Cancer Research</i> , (March 1999) 5:695-703.	
	BJ	Muindi, J. et al., "Pharmacokinetics of High-Dose Oral Calcitriol: Results From a Phase I Trial of Calcitriol and Paclitaxel," <i>Clinical Pharmacology & Therapeutics</i> , (Dec. 2002) pp. 648-659.	
	BK	Nemeto, H. et al., "A Stereoselective Synthesis of 1 α - Hydroxy-Vitamin D ₃ ," <i>CHEMISTRY LETTERS</i> , (1985) 8:1131-1132.	
	BL	Paaren et al., "Direct C(1) Hydroxylation of Vitamin D ₃ and Related Compounds," <i>J. Org. Chem.</i> , (1980) 45:3253.	
	BM	Packman, K. et al. "Combination Treatment of MCF-7 Xenografts with the Vitamin D ₃ Analog EB1089 and Antiestrogens," (Vitamin D Endocrine Workshop, Nashville, TN May 27-June 1, 2000) pp. 511-514.	
<i>th</i>	BN	Podenphant, J. et al., "Serum Bone Gla Protein and Other Biochemical Estimates of Bone Turnover in Early Postmenopausal Women During Prophylactic Treatment for Osteoporosis," <i>Acta Med Scand</i> , (1985) 218:329-333.	
<i>th</i>	BO	Physician's Desk Reference, Edition 43:1746-1748-	<i>Need Date</i>
<i>th</i>	BP	Pouilles, J.M. et al., "Prevention of Early Postmenopausal Bone Loss with 1 α -Hydroxy Vitamin D ₃ , A Three-Year Prospective Study," <i>Clin Rheumatol.</i> 11, 4 (1992) pp. 492-497.	
	BQ	Ravid, A. et al., "1,25-Dihydroxyvitamin D ₃ Enhances the Susceptibility of Breast Cancer Cells to Doxorubicin-induced Oxidative Damage," <i>Cancer Research</i> , (February 15, 1999) 59:862-867.	
	BR	Reeve, L.E. et al., "Biological Activity of 1 α -hydroxy Vitamin D ₂ in the Rat," <i>Arch. Biochem. Biophys.</i> (Feb. 1978) 186:1:164-167.	
<i>th</i>	BS	Sato, F. et al., "Biological Activity of 1 α ,25-Dihydroxyvitamin D Derivatives - 24- <i>epi</i> -1 α ,25-Dihydroxyvitamin D-2 and 1 α ,25-Dihydroxyvitamin D-7," <i>Biochim. Biophys. Acta</i> , (1991) 1091:188-192.	

Examiner Signature	<i>th</i>	Date Considered	6/15/04
-----------------------	-----------	--------------------	---------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231.
DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	09/753,697
				Filing Date	January 3, 2001
				First Named Inventor	Charles W. Bishop
				Group Art Unit	1617
				Examiner Name	Theodore J. Criares
Sheet	4	of	5	Attorney Docket Number	017620-9316

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, pages(s), volume-issue numbers(s), publisher, city and/or country where published.

BT	Siwinska, A. et al. "Potentiation of the Antiproliferative Effect <i>in Vitro</i> of Doxorubicin, Cisplatin and Genistein by New Analogues of Vitamin D," <i>Anticancer Research</i> , (2001) 21:1925-1929.
BU	Sjoden et al., "Effects of 1 OHD ₂ on Bone Tissue," <i>Acta. Endocrinol.</i> (Copenh.) (Aug. 1984) 16:4:564-568.
BV	Skowronski et al., "Vitamin D and Prostate Cancer: 1,25 Dihydroxyvitamin D ₃ Receptors and Actions in Human Prostate Cancer Cell Lines," <i>Endocrinology</i> , (1993) 132:1952-1960.
BW	Slapak, C. et al., "Treatment of Acute Myeloid Leukemia in the Elderly with Low-Dose Cytarabine, Hydroxyurea, and Calcitriol," <i>Amer. J. Hematology</i> , (1992) 41:178-183.
BX	Sommerfeldt et al., "Metabolism of Orally Administered [³ H]Ergocalciferol and [³ H]Cholecalciferol by Dairy Calves," <i>J. Nutr.</i> , (1983) 11:2595-2600.
BY	Song, X.D. et al., "Bryostatin-1 and 1 α ,25-Dihydroxyvitamin D ₃ Synergistically Stimulate the Differentiation of NB4 Acute Promyelocytic Leukemia Cells," <i>Leukemia</i> , (1999) 13:275-281.
BZ	Studzinski, G. et al., "Potentiation by 1- α ,25-Dihydroxyvitamin D ₃ of Cytotoxicity to HL-60 Cells Produced by Cytarabine and Hydroxyurea," <i>J. National Cancer Inst.</i> , (April 1986) 76:4:641-648.
CA	Strugnell et al., "Metabolism of a Cyclopropane-Ring-Containing Analog of 1 α -Hydroxyvitamin D ₃ in a Hepatocyte Cell Model," <i>Biochem. Pharm.</i> , (1990) 40:333-341.
CB	Suzuki, Y. et al., "The Enhancement of the Chemotherapeutic Effects on Human Prostate Cancer Cell - The Combination with the Growth Factor Interaction Inhibitor (Suramin)," <i>Acta Urologica</i> (1993) 12:1215-1220, (Abstract).
CC	Swami, S. et al. "1 α ,25-Dihydroxyvitamin D ₃ Down-Regulates Estrogen Receptor Abundance and Suppresses Estrogen Actions in MCF-7 Human Breast Cancer Cells," <i>Clinical Cancer Research</i> , (Aug. 2000) 6:3371-3379.
CD	Tachibana, Y. (Nisshin Flour Milling Co.), "Preparation of 1Beta-Hydroxyvitamin D ₂ and D ₃ ," <i>CHEMICAL ABSTRACTS</i> , (1990) 113:1:6688 Col. 2 Abstract No. 6683y.
CE	Tanaka, Y. et al., <i>Endocrinology</i> (1973) 92:417-422.
CF	Torres, R. et al., "Etoposide Stimulates 1,25-Dihydroxyvitamin D ₃ Differentiation Activity, Hormone Binding and Hormone Receptor Expression in HL-60 Human Promyelocytic Cells, <i>Molecular and Cellular Biochemistry</i> , (2000) 208:157-162.
CG	Tsuji, M. et al., "Synthesis of 22,23-Dihydro-1 α ,25-Dihydroxyvitamin D ₂ and its 24R-Epimer, New Vitamin D ₂ Derivatives," <i>Bull. Chem. Soc. Jpn.</i> , (1990) 63:8:2233-2238.

Examiner Signature		Date Considered	6/15/04
--------------------	---	-----------------	---------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231.
DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	09/753,697
				Filing Date	January 3, 2001
				First Named Inventor	Charles W. Bishop
				Group Art Unit	1617
				Examiner Name	Theodore J. Criares
Sheet	5	of	5	Attorney Docket Number	017620-9316

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, pages(s), volume-issue numbers(s), publisher, city and/or country where published.

CH	Wang, Q. et al., "1,25-Dihydroxyvitamin D ₃ and All- <i>trans</i> -Retinoic Acid Sensitize Breast Cancer Cells to Chemotherapy-induced Cell Death," <i>Cancer Research</i> , (April 2000) 60:2040-2048.
CI	Wang, X. et al., "Inhibition of p38 MAP Kinase Activity Up-Regulates Multiple MAP Kinase Pathways and Potentiates 1,25-Dihydroxyvitamin D ₃ -Induced Differentiation of Human Leukemia HL60 Cells," <i>Experimental Cell Research</i> , (2000) 258:425-437.
CJ	Wientroub, S. et al. "The Dichotomy in the Effects of 1,25 Dihydroxy Vitamin D ₃ and 24, 25 Dihydroxy Vitamin D ₃ on Bone Gamma-Carboxyglutamic Acid-Containing Protein in Serum and Bone in Vitamin D-Deficient Rats," <i>Calcif. Tissue Int.</i> , (1987) 40:166-172.
CK	Windaus, A. et al., "Über das Krystallisierte Vitamin D ₄ ," <i>Z. Physiol. Chem.</i> , (1937) 247:185-188.
CL	Yu, W. et al., "Enhancement of 1,25- Dihydroxyvitamin D ₃ - Mediated Antitumor Activity with Dexamethasone," <i>J. National Cancer Inst.</i> , (January 1998) 90:2:134-141.
CM	Zerwekh et al., "Short-Term 1,25-Dihydroxyvitamin D ₃ Administration Raises Serum Osteocalcin in Patients with Postmenopausal Osteoporosis," <i>J. Clin. Endocrinol. Metabol</i> , (1985) 60:615-617.

Examiner Signature		Date Considered	6/15/04
-----------------------	---	--------------------	---------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231.
DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.